Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,317 INR | -1.39% | +3.10% | -10.00% |
26/04 | Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024 | CI |
18/03 | Dr Lal Pathlabs Names CEO | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analyst opinion has improved significantly over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With an expected P/E ratio at 54.98 and 47.27 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.00% | 2.34B | B | ||
-18.58% | 8.15B | B+ | ||
+48.66% | 3.82B | C+ | ||
-8.06% | 2.47B | - | ||
-38.71% | 2.46B | B- | ||
-9.02% | 1.88B | C- | ||
-19.29% | 1.55B | A- | ||
-40.78% | 1.21B | C+ | ||
+8.32% | 1.11B | B+ | ||
-23.31% | 1.06B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LALPATHLAB Stock
- LALPATHLAB Stock
- Ratings Dr. Lal PathLabs Limited